Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)

Robert Z. Orlowski, M.D., Ph.D, Shadia Zaman, Ph.D., Sheeba K. Thomas, M.D., Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, MD, Ashley N. Holloway, R.N., Veerabhadran Baladandayuthapani, Ph.D., Heather Yan Lin, Ph.D., Min Fu, Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha Gandhi, PhD

Blood (2013) 122 (21): 1953.

https://doi.org/10.1182/blood.V122.21.1953.1953

Published: 2013

Journal Articles

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma

Paul G. Richardson, MD, Robert L. Schlossman, MD, Melissa Alsina, MD, Donna M. Weber, M.D., Steven E. Coutre, MD, Cristina Gasparetto, MD, Sutapa Mukhopadhyay, PhD, Michael S. Ondovik, PharmD, MBA, Mahmudul Khan, PhD, Carole S. Paley, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 1970.

https://doi.org/10.1182/blood.V122.21.1970.1970

Published: 2013

Journal Articles

Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Jatin J. Shah, M.D., Lei Feng, M.S., Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Brandi Hilder, Raymond Alexanian, M.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 1982.

https://doi.org/10.1182/blood.V122.21.1982.1982

Published: 2013

Journal Articles

Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma

Jatin J. Shah, M.D., Veera Baladandayuthapani, PhD, Donna M. Weber, M.D., Sheeba K. Thomas, M.D., Raymond Alexanian, M.D., Michael Wang, MD, Muzaffar H. Qazilbash, MD, Richard E Champlin, MD, Nina Shah, MD, Qaiser Bashir, MD, Uday R Popat, MD, Yago Nieto, M.D., Ph.D., Sairah Ahmed, MD, Simrit Parmar, MD, Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 1983.

https://doi.org/10.1182/blood.V122.21.1983.1983

Published: 2013

Journal Articles

Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib

Arti Alagappan, Rupin A Shah, M.B.B.S, Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Raymond Alexanian, M.D., Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 1994.

https://doi.org/10.1182/blood.V122.21.1994.1994

Published: 2013

Journal Articles

Plasmablastic Lymphoma: 28 Patient Single Institution Experience

Krina Patel, MD, Lei Feng, M.S., Yasuhiro Oki, MD, Muzaffar Qazilbash, M.D., Tariq Muzzafar, MBBS, Donna M. Weber, M.D., Nathan Fowler, MD, Uday R Popat, MD, Sheeba K. Thomas, M.D., Michelle A. Fanale, MD, Yago Nieto, MD, PhD, Nina Shah, MD, Qaiser Bashir, MD, Fredrick B. Hagemeister, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 4310.

https://doi.org/10.1182/blood.V122.21.4310.4310

Published: 2013

Journal Articles

Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia

Rupin A Shah, M.B.B.S, Satyajit Mohite, M.B.B.S., Veerabhadran Baladandayuthapani, Ph.D., Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Raymond Alexanian, M.D., Muzaffar H Qazilbash, MD, Uday R Popat, MD, Richard E Champlin, MD, Nina Shah, MD, Qaiser Bashir, MD, Simrit Parmar, MD, Yago Nieto, MD, PhD, Sairah Ahmed, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.

Blood (2013) 122 (21): 5356.

https://doi.org/10.1182/blood.V122.21.5356.5356

Published: 2013

Journal Articles

A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM)

Sheeba K. Thomas, M.D., Tamara M Haygood, M.D., Muzaffar H. Qazilbash, MD, A. Georgina Melendez, M.D., Roxana Galvis, Kay B Delasalle, B.S., Lei Feng, M.S., Tiffany A. Richards, M.S., Felipe Samaniego, M.D., M.P.H, Luhua Wang, M.D., Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D., Donna M. Weber, M.D.

Blood (2013) 122 (21): 4396.

https://doi.org/10.1182/blood.V122.21.4396.4396

Published: 2013

Journal Articles

Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study

Sagar Lonial, M.D., Jatin J. Shah, M.D., Jeffrey Zonder, M.D., William I. Bensinger, MD, Adam D. Cohen, MD, Jonathan L. Kaufman, MD, Ajay K. Nooka, MD, MPH, Donna M. Weber, M.D., Brandi Hilder, Selena A Rush, BS, Ann Ptaszynski, Duncan Walker, PhD, Robert Z. Orlowski, M.D., Ph.D.

Blood (2013) 122 (21): 285.

https://doi.org/10.1182/blood.V122.21.285.285

Published: 2013

Journal Articles

Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.

Jatin J. Shah, M.D., Aparna Hegde, MD, Xiao Zhou, MD, PHD, Sheeba K. Thomas, MD, Michael Wang, MD, Donna M. Weber, M.D., Raymond Alexanian, MD, Robert Z. Orlowski, MD, PhD, Saroj Vadhan-Raj, MD

Blood (2012) 120 (21): 2244.

https://doi.org/10.1182/blood.V120.21.2244.2244

Published: 2012

Journal Articles

Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia

Isere Kuiatse, Ph.D., Sheeba K. Thomas, MD, Donna M. Weber, M.D., Adam M. Stein, B.S., Michael Wang, M.D., Jatin J. Shah, M.D., Steven P. Treon, M.D., Ph.D., Stephen M. Ansell, M.D., Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 3723.

https://doi.org/10.1182/blood.V120.21.3723.3723

Published: 2012

Journal Articles

Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Jatin J. Shah, M.D., Sheeba K. Thomas, MD, Donna M. Weber, M.D., Michael Wang, M.D., Raymond Alexanian, M.D., Muzaffar H. Qazilbash, MD, Qaiser Bashir, MD, Simrit Parmar, M.D., Nina Shah, MD, Uday R. Popat, M.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 4081.

https://doi.org/10.1182/blood.V120.21.4081.4081

Published: 2012

Journal Articles

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Jatin J. Shah, M.D., Donna M. Weber, M.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Michael Wang, M.D., Muzaffar H. Qazilbash, MD, Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, MD, Uday R. Popat, M.D., Brandi Hilder, Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 4082.

https://doi.org/10.1182/blood.V120.21.4082.4082

Published: 2012

Journal Articles

Impact of Rituximab On the Treatment of Waldenström's Macroglobulinemia (WM).

Sheeba K. Thomas, MD, Kay B Delasalle, B.S., Jatin J. Shah, M.D., Luhua Wang, M.D., Robert Z. Orlowski, M.D., Ph.D., Donna M. Weber, M.D.

Blood (2012) 120 (21): 2734.

https://doi.org/10.1182/blood.V120.21.2734.2734

Published: 2012

Journal Articles

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Stephan Joseph Dorkhom, D.O., Shadia Zaman, Ph.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, M.D., Martha L. Anderson, R.N., Veerabhadran Baladandayuthapani, Ph.D., Yan Heather Lin, Ph.D., Min Fu, Ph.D., Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha V. Gandhi, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2012) 120 (21): 2976.

https://doi.org/10.1182/blood.V120.21.2976.2976

Published: 2012

Journal Articles

Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma

Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Michael Wang, M.D., Muzaffar H. Qazilbash, MD, Uday R. Popat, M.D., Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, Richard E. Champlin, Donna M. Weber, M.D.

Blood (2012) 120 (21): 75.

https://doi.org/10.1182/blood.V120.21.75.75

Published: 2012

Journal Articles

Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom's Macroglobulinemia

Dilshad Khan, MBBS, Krina Patel, MD, Sheeba K. Thomas, MD, Donna M. Weber, M.D., Kay B Delasalle, B.S., Chitra M. Hosing, M.D., Uday R. Popat, M.D., Qaiser Bashir, MD, Nina Shah, MD, Simrit Parmar, M.D., Richard E. Champlin, Muzaffar Qazilbash, M.D.

Blood (2012) 120 (21): 4128.

https://doi.org/10.1182/blood.V120.21.4128.4128

Published: 2012

Journal Articles

Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups.

Sheeba K Thomas, M.D., Lei Feng, M.S., Kay B Delasalle, B.S., Michael Wang, M.D., Jatin J Shah, M.D., Robert Z Orlowski, M.D., Ph.D., Raymond Alexanian, M.D., Donna M Weber, M.D.

Blood (2009) 114 (22): 1668.

https://doi.org/10.1182/blood.V114.22.1668.1668

Published: 2009

Journal Articles

Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation.

Nina Shah, MD, Donna M Weber, M.D., Michael Wang, MD, Sheeba Thomas, MD, Jatin Shah, MD, Sergio Giralt, MD, Raymond Alexanian, M.D., Robert Z Orlowski, M.D., Ph.D., Muzaffar H. Qazilbash, MD, Tiffany Avery, M.D., MPH

Blood (2009) 114 (22): 1395.

https://doi.org/10.1182/blood.V114.22.1395.1395

Published: 2009

Journal Articles

Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma.

Nina Shah, MD, Khawaja Fraz Ahmed, Sofia Qureshi, Jatin Shah, MD, Robert Z Orlowski, M.D., Ph.D., Donna M Weber, M.D., Chitra Hosing, Uday Popat, MD, Amin Alousi, MD, Richard E Champlin, MD, Sergio Giralt, M.D., Muzaffar Qazilbash, MD

Blood (2009) 114 (22): 1227.

https://doi.org/10.1182/blood.V114.22.1227.1227

Published: 2009

NARROW

Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)

Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma

Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma

Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib

Plasmablastic Lymphoma: 28 Patient Single Institution Experience

Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia

A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM)

Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study

Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.

Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia

Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Impact of Rituximab On the Treatment of Waldenström's Macroglobulinemia (WM).

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma

Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom's Macroglobulinemia

Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups.

Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation.

Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only